International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 202 Thousand USD | -2231.82% |
| 2022 | 22 Thousand USD | 101.34% |
| 2021 | -220 Thousand USD | 35.83% |
| 2020 | -2.35 Million USD | 52.86% |
| 2019 | -3.9 Million USD | -73.11% |
| 2018 | -1.77 Million USD | 31.91% |
| 2017 | -5.68 Million USD | 15.27% |
| 2016 | 186 Thousand USD | -33.14% |
| 2015 | -2.15 Million USD | 55.61% |
| 2014 | -12.01 Million USD | -30.18% |
| 2013 | -10.01 Million USD | 27.83% |
| 2012 | -9.35 Million USD | 9.64% |
| 2011 | -8.67 Million USD | -7.04% |
| 2010 | -9.59 Million USD | -45.27% |
| 2009 | -7.47 Million USD | -30.09% |
| 2008 | -5.35 Million USD | 9.79% |
| 2007 | -5.89 Million USD | -7.19% |
| 2006 | -5.63 Million USD | -66818.5% |
| 2005 | -1.23 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -129 Thousand USD | 65.69% |
| 2024 Q2 | 199 Thousand USD | 254.26% |
| 2023 Q4 | -376 Thousand USD | -287.63% |
| 2023 Q1 | 53 Thousand USD | -50.93% |
| 2023 Q2 | 575 Thousand USD | 984.91% |
| 2023 FY | - USD | -2231.82% |
| 2023 Q3 | -97 Thousand USD | -116.87% |
| 2022 Q2 | 86 Thousand USD | 6.17% |
| 2022 FY | - USD | 101.34% |
| 2022 Q4 | 108 Thousand USD | 142.69% |
| 2022 Q3 | -253 Thousand USD | -394.19% |
| 2022 Q1 | 81 Thousand USD | 133.33% |
| 2021 Q2 | -342 Thousand USD | 31.74% |
| 2021 Q3 | -558 Thousand USD | -63.16% |
| 2021 FY | - USD | 35.83% |
| 2021 Q1 | -501 Thousand USD | 25.45% |
| 2021 Q4 | -243 Thousand USD | 56.45% |
| 2020 Q2 | -767 Thousand USD | -95.66% |
| 2020 FY | - USD | 52.86% |
| 2020 Q3 | -734 Thousand USD | 4.3% |
| 2020 Q4 | -672 Thousand USD | 8.45% |
| 2020 Q1 | -392 Thousand USD | 83.68% |
| 2019 Q1 | -1.39 Million USD | -17.66% |
| 2019 Q4 | -2.4 Million USD | -221.12% |
| 2019 FY | - USD | -73.11% |
| 2019 Q2 | -891 Thousand USD | 36.31% |
| 2019 Q3 | -748 Thousand USD | 16.05% |
| 2018 Q2 | -293 Thousand USD | 73.72% |
| 2018 Q4 | -1.18 Million USD | -118.17% |
| 2018 FY | - USD | 31.91% |
| 2018 Q1 | -1.11 Million USD | 39.6% |
| 2018 Q3 | -545 Thousand USD | -86.01% |
| 2017 Q3 | -887 Thousand USD | 3.48% |
| 2017 FY | - USD | 15.27% |
| 2017 Q1 | -964 Thousand USD | 11.4% |
| 2017 Q4 | -1.84 Million USD | -108.12% |
| 2017 Q2 | -919 Thousand USD | 4.67% |
| 2016 FY | - USD | -33.14% |
| 2016 Q4 | -1.08 Million USD | 61.92% |
| 2016 Q3 | -2.85 Million USD | -132.47% |
| 2016 Q2 | -1.22 Million USD | 36.97% |
| 2016 Q1 | -1.95 Million USD | -119.84% |
| 2015 Q3 | -508 Thousand USD | 41.07% |
| 2015 Q2 | -862 Thousand USD | 53.02% |
| 2015 FY | - USD | 55.61% |
| 2015 Q1 | -1.83 Million USD | 43.12% |
| 2015 Q4 | -887 Thousand USD | -74.61% |
| 2014 FY | - USD | -30.18% |
| 2014 Q4 | -3.22 Million USD | -68.11% |
| 2014 Q1 | -1.94 Million USD | 50.32% |
| 2014 Q2 | -2.12 Million USD | -9.03% |
| 2014 Q3 | -1.91 Million USD | 9.69% |
| 2013 Q4 | -3.92 Million USD | -870.73% |
| 2013 FY | - USD | 27.83% |
| 2013 Q1 | -1.58 Million USD | 36.23% |
| 2013 Q2 | -2.06 Million USD | -30.62% |
| 2013 Q3 | 509 Thousand USD | 124.6% |
| 2012 Q4 | -2.48 Million USD | -19.42% |
| 2012 FY | - USD | 9.64% |
| 2012 Q1 | -2.59 Million USD | 7.25% |
| 2012 Q2 | -2.3 Million USD | 11.22% |
| 2012 Q3 | -2.08 Million USD | 9.68% |
| 2011 Q3 | -2.98 Million USD | -9.43% |
| 2011 Q2 | -2.72 Million USD | -24.09% |
| 2011 FY | - USD | -7.04% |
| 2011 Q1 | -2.19 Million USD | 15.16% |
| 2011 Q4 | -2.79 Million USD | 6.28% |
| 2010 Q2 | -2.78 Million USD | -34.17% |
| 2010 Q1 | -2.07 Million USD | -52.27% |
| 2010 FY | - USD | -45.27% |
| 2010 Q3 | -2.87 Million USD | -3.07% |
| 2010 Q4 | -2.59 Million USD | 9.76% |
| 2009 Q1 | -1.84 Million USD | -44.21% |
| 2009 Q4 | -1.36 Million USD | 32.26% |
| 2009 Q3 | -2.01 Million USD | 1.99% |
| 2009 Q2 | -2.05 Million USD | -11.17% |
| 2009 FY | - USD | -30.09% |
| 2008 Q4 | -1.28 Million USD | -254.62% |
| 2008 Q2 | -1.63 Million USD | -3.95% |
| 2008 Q1 | -1.57 Million USD | -13.12% |
| 2008 FY | - USD | 9.79% |
| 2008 Q3 | -361.12 Thousand USD | 77.94% |
| 2007 FY | - USD | -7.19% |
| 2007 Q4 | -1.39 Million USD | 4.73% |
| 2007 Q1 | -1.75 Million USD | 69.19% |
| 2007 Q2 | -1.72 Million USD | 1.6% |
| 2007 Q3 | -1.46 Million USD | 15.33% |
| 2006 Q2 | -1122.00 USD | 91.19% |
| 2006 FY | - USD | -66818.5% |
| 2006 Q1 | -12.74 Thousand USD | 0.0% |
| 2006 Q4 | -5.69 Million USD | -54688.87% |
| 2006 Q3 | -10.38 Thousand USD | -825.85% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | 101.163% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 131.942% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 61.701% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 155.008% |
| Qrons Inc. | -40.08 Thousand USD | 603.979% |
| Rebus Holdings, Inc. | -951 Thousand USD | 121.241% |
| Skye Bioscience, Inc. | -13.54 Million USD | 101.491% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 99.785% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.365% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 101.273% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 105.2% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.284% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 103.407% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 184.466% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.315% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 107.639% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 113.151% |
| Mesoblast Limited | -62.38 Million USD | 100.324% |
| Marizyme, Inc. | -34.28 Million USD | 100.589% |
| Genus plc | 73.7 Million USD | 99.726% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 103.055% |
| Pharming Group N.V. | 9.87 Million USD | 97.955% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 113.581% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 105.695% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 102.303% |
| ContraFect Corporation | -64.99 Million USD | 100.311% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 104.463% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 114.41% |
| IMV Inc. | -35.52 Million USD | 100.569% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 108.693% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 138.993% |
| ONE Bio Corp. | 13.61 Million USD | 98.516% |
| Accustem Sciences Inc. | -3.74 Million USD | 105.392% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.419% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 115.942% |
| Q BioMed Inc. | -617.62 Thousand USD | 132.706% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 94.345% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 108.842% |
| Biomind Labs Inc. | -1.03 Million USD | 119.525% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.51% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 106.984% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 102.821% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -2904.164% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 908.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 108.074% |
| GB Sciences, Inc. | -1.41 Million USD | 114.227% |
| Alpha Cognition Inc. | -9.7 Million USD | 102.081% |
| HST Global, Inc. | -5303.00 USD | 3909.165% |
| CSL Limited | 4.78 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 109.82% |
| Halberd Corporation | -74.27 Thousand USD | 371.948% |
| Enzolytics Inc. | -2.12 Million USD | 109.519% |
| Agentix Corp. | -1.37 Million USD | 114.726% |
| Resverlogix Corp. | -11.74 Million USD | 101.72% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 106.595% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 100.094% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 83.402% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 97.718% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 113.476% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 46.68% |
| AVAX Technologies, Inc. | -6.11 Million USD | 103.305% |
| Zenith Capital Corp. | -8.6 Million USD | 102.347% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.081% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1259.52% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 108.257% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 214.757% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 110.516% |
| Kadimastem Ltd | -2.62 Million USD | 107.697% |
| Helix BioMedix, Inc. | -1.04 Million USD | 119.306% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 111.543% |
| BioStem Technologies, Inc. | -7.55 Million USD | 102.674% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 211.548% |
| LadRx Corporation | 412.28 Thousand USD | 51.005% |
| Cell Source, Inc. | -4.27 Million USD | 104.728% |
| Regen BioPharma, Inc. | 1.46 Million USD | 86.221% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 121.559% |
| NovAccess Global Inc. | -1.03 Million USD | 119.521% |
| Affymax, Inc. | -14.29 Million USD | 101.413% |
| Itoco Inc. | -1.86 Million USD | 110.808% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 153.211% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 118.1% |
| Mobile Lads Corp. | -2.24 Million USD | 109.013% |
| CytoDyn Inc. | -18.02 Million USD | 101.12% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 355.602% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 1751.811% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 141.591% |
| SYBLEU INC | -141.57 Thousand USD | 242.685% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 119.021% |
| Bioxytran, Inc. | -3.82 Million USD | 105.288% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 483.739% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 108.205% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 100.563% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 548.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 107.378% |
| Neutra Corp. | -181.24 Thousand USD | 211.45% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 101.002% |
| PureTech Health plc | -11.62 Million USD | 101.737% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 101.002% |
| IXICO plc | -707 Thousand USD | 128.571% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 102.628% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.418% |
| CSL Limited | 4.73 Billion USD | 99.996% |
| Cellectis S.A. | -92.63 Million USD | 100.218% |